Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer

Mohammed, Azharuddin; Arastu, Zubair

doi:10.1186/s12894-017-0304-5

Cited by 16 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,5 Toxicity is reported to be dose-dependent and strain-specific. 6 Antituberculous drugs administration and low-dose steroid treatment are suggested as empirical therapy in suspected cases. 4 Despite scanty literature data, other infectious causes of bone marrow granulomatosis in patients presenting with pancytopenia and fever include Leishmania, Brucella, Coxiella burnetii (Q fever), Bartonella, EBV, CMV.…”

Section: Discussionmentioning

confidence: 99%

Bone marrow granulomatosis: two case reports

et al. 2019

View full text Add to dashboard Cite

Bone marrow granulomatosis is not a common finding and remains a diagnostic challenge. Here below we report two bizarre but not so rare cases of bone marrow granulomatosis: bone marrow involvement by Mycobacterium avium-intracellulare and reaction to intravesical administration of Bacillus Calmette-Guérin for non-muscle-invasive bladder cancer; two distinct culprits suggesting the wide range of possible causative factors of this histopathological pattern. In the discussion we provide a brief overview of causes and suggestions for a diagnostic approach.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone marrow granulomatosis: two case reports

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The majority of described cases referred to AKI caused by interstitial nephritis. In these cases, the therapy with glucocorticoids was administered and in three out of eight patients the renal function recovered [ 188 , 189 , 190 ]. The other single cases include nephritis in the course of Henoch–Schönlein purpura [ 191 ] and membranous glomerulonephritis with clinical presentation of nephrotic syndrome [ 192 ].…”

Section: Therapeutic Cancer Vaccinesmentioning

confidence: 99%

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Borówka

Łącki-Zynzeling

Nicze

et al. 2022

Cancers

View full text Add to dashboard Cite

Modern oncological therapy utilizes various types of immunotherapy. Immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cells (CAR-T) therapy, cancer vaccines, tumor-targeting monoclonal antibodies (TT-mAbs), bispecific antibodies and cytokine therapy improve patients’ outcomes. However, stimulation of the immune system, beneficial in terms of fighting against cancer, generates the risk of harm to other cells in a patient’s body. Kidney damage belongs to the relatively rare adverse events (AEs). Best described, but still, superficially, are renal AEs in patients treated with ICIs. International guidelines issued by the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) cover the management of immune-related adverse events (irAEs) during ICI therapy. There are fewer data concerning real occurrence and possible presentations of renal adverse drug reactions of other immunotherapeutic methods. This implies the need for the collection of safety data during ongoing clinical trials and in the real-life world to characterize the hazard related to the use of new immunotherapies and management of irAEs.

show abstract

“…The majority of described cases referred to AKI caused by interstitial nephritis. In these cases, the therapy with glucocorticoids was administered and in three out of eight patients the renal function recovered [144][145][146]. The other single cases include nephritis in the course of Henoch Schönlein Purpura [147] and membranous glomerulonephritis with clinical presentation of nephrotic syndrome [148].…”

Section: Renal Adverse Effectsmentioning

confidence: 99%

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Borówka¹,

Łącki-Zynzeling²,

Nicze³

et al. 2022

Preprint

View full text Add to dashboard Cite

Modern oncological therapy utilizes various types of immunotherapy. Immune checkpoint inhib-itors (ICIs), chimeric antigen receptor T cells (CAR-T) therapy, cancer vaccines and bispecific an-tibodies are improving patients’ outcomes. However, stimulation of the immune system, benefi-cial in terms of fighting against cancer, generates the risk of harm to other cells in a patient's body. Kidney damage belongs to the relatively rare adverse events (AEs). Best described, but still, su-perficially, are renal AEs in patients treated with ICIs. International guidelines issued by Euro-pean Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) cover the management of immune-related adverse events (irAEs) during ICI therapy. There are scarce data concerning renal adverse drug reactions of other immunotherapeutic methods. This implicates the need for the collection of safety data during ongoing clinical trials and in the re-al-life world to characterize the hazard related to the use of new immunotherapies and manage-ment of irAEs.

show abstract

Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer

Cited by 16 publications

References 22 publications

Bone marrow granulomatosis: two case reports

Bone marrow granulomatosis: two case reports

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Contact Info

Product

Resources

About